(MENAFNEditorial) Marking an unprecedented step, Dar Al Dawa - leading pharmaceutical manufacturer in Jordan and the Middle East - has organized its first symposium, entitled 'Global Healthcare Issues'. Held on Monday 4 May, 2015, in Amman, the event hosted renowned international expert, Dr. Brian Tempest, who specializes in pharmaceutical and chemical manufacturing company management. Also present were a group of physicians and pharmacists from the public and private sectors, in addition to representatives from Dar Al Dawa.
During the symposium, Dar Al Dawa CEO, Eng. Amer Al Khatib, shared the Company's most recent activities and accomplishments regarding drug manufacture, and spoke about Dar Al Dawa's instrumental role in supplying high quality and competitively priced generic drugs to Arab markets, thus actively contributing to reducing treatment costs for both citizens and governments throughout the region. Alternatively, Dar Al Dawa Research and Development Director, Dr. Ismail Khalifeh, delivered a presentation on generic drug development methods.
In turn, Dr. Tempest touched on several topics including key global healthcare issues, research and development efforts within the sector, as well as the role of private hospitals in enhancing healthcare and medical tourism. Dr. Tempest also tackled the latest advancements within the worldwide generic drug industry, and highlighted its vital role in helping governments provide comprehensive and affordable healthcare services to citizens.
Moreover, Dar Al Dawa Marketing Director, Dr. Abdalla Mazahreh, described the symposium as an integral step towards boosting confidence in the quality and effectiveness of the generic drugs developed and manufactured by the Company, and stressed the importance of establishing strategic partnerships with various sectors to deliver premium quality medications.
Dar Al Dawa was founded in 1975 as a public shareholding company headquartered in Amman, Jordan. Since its inception, Dar Al Dawa has cemented its position as a leading pharmaceutical company within the region, providing products to over 40 countries across the Middle East and Europe. Today, Dar Al Dawa employs more than 900 staff worldwide, and has in excess of 100 products and 200 dosage forms covering over 20 therapeutic classes. Dar Al Dawa's manufacturing facilities are Good Manufacturing Practice (GMP) certified, underscoring the Company's commitment to delivering medical treatments that are on par with global standards.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.